Bicycle Therapeutics plc (NASDAQ:BCYC) went down by -0.48% from its latest closing price compared to the recent 1-year high of $55.90. The company’s stock price has collected 21.38% of gains in the last five trading sessions. Press Release reported 9 hours ago that Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
Is It Worth Investing in Bicycle Therapeutics plc (NASDAQ :BCYC) Right Now?
Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for Bicycle Therapeutics plc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $69.30, which is -$9.58 below the current price. BCYC currently public float of 2.95M and currently shorts hold a 15.56% ratio of that float. Today, the average trading volume of BCYC was 280.91K shares.
BCYC’s Market Performance
BCYC stocks went up by 21.38% for the week, with a monthly jump of 38.00% and a quarterly performance of 61.18%, while its annual performance rate touched 187.05%. The volatility ratio for the week stands at 20.66% while the volatility levels for the past 30 days are set at 10.53% for Bicycle Therapeutics plc. The simple moving average for the period of the last 20 days is 21.18% for BCYC stocks with a simple moving average of 75.72% for the last 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with B. Riley Securities repeating the rating for BCYC by listing it as a “Buy.” The predicted price for BCYC in the upcoming period, according to B. Riley Securities is $56 based on the research report published on September 30th of the current year 2021.
JMP Securities, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $53. The rating they have provided for BCYC stocks is “Mkt Outperform” according to the report published on April 20th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to BCYC, setting the target price at $30 in the report published on October 12th of the previous year.
BCYC Trading at 42.80% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.95% of loss for the given period.
Volatility was left at 10.53%, however, over the last 30 days, the volatility rate increased by 20.66%, as shares surge +23.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +82.97% upper at present.
During the last 5 trading sessions, BCYC rose by +30.10%, which changed the moving average for the period of 200-days by +180.94% in comparison to the 20-day moving average, which settled at $45.29. In addition, Bicycle Therapeutics plc saw 203.68% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BCYC starting from Keen Nicholas, who sale 2,178 shares at the price of $45.10 back on Oct 05. After this action, Keen Nicholas now owns 0 shares of Bicycle Therapeutics plc, valued at $98,228 using the latest closing price.
Keen Nicholas, the Chief Scientific Officer of Bicycle Therapeutics plc, sale 1,188 shares at $45.00 during a trade that took place back on Oct 01, which means that Keen Nicholas is holding 2,178 shares at $53,460 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -512.37 for the present operating margin
The net margin for Bicycle Therapeutics plc stands at -490.95. The total capital return value is set at -52.00, while invested capital returns managed to touch -50.19. Equity return is now at value -50.40, with -31.60 for asset returns.
Based on Bicycle Therapeutics plc (BCYC), the company’s capital structure generated 16.53 points at debt to equity in total, while total debt to capital is 14.18. Total debt to assets is 9.79, with long-term debt to equity ratio resting at 15.64. Finally, the long-term debt to capital ratio is 13.42.
When we switch over and look at the enterprise to sales, we see a ratio of 9.43, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 0.96 and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.73.